Ibyiza bya paclitaxel ya Albumin

Paclitaxel ni umwe mu miti itatu ya chimiotherapie ya chimiotherapie, ariko ubushobozi bwayo bwo gukemura amazi ni mibi kandi igomba gushonga hamwe n’umuti ukomoka ku binyabuzima. gusa irinda hypersensitivite / toxicity reaction iterwa na solge organic, ariko kandi ntibisaba kwitegura imisemburo ya hormone; Irashobora kandi gutuma albumin itwara paclitaxel ikava mumaraso byihuse, ikanyura muri selile endothelia ikoresheje reseptor medrated endocytose, kandi ikungahaza cyane mubice byibyimba. binyuze murwego rwo hejuru rwo kwifata no kugumana (EPR ingaruka) yibibyimba, bikomeje kwerekana ibyiza bya farumasi.

Mu gihe cyo gukingira indwara, ingaruka z’imiti imwe ntabwo zihagije, kandi igipimo cyo kohereza (ORR) cy’imiti imwe ntigishobora kurenga 20%; Uburyo bwo kwagura abagenerwabikorwa b’ubudahangarwa, kuvura hamwe bishobora kuba igisubizo cyiza, muri byo uburyo bwa chimiotherapie hamwe ni ahantu hashyushye mubushakashatsi bugezweho.

Dufatiye kuri iyi ngingo, paclitaxel ihujwe na Albumin ifite ibyiza byayo, ORR yayo iri hejuru, irashobora kwica selile yibibyimba neza, kandi igateza imbere kwandura antigen yibibyimba; Nta miti ya hormone ikenewe kugirango wirinde gukingira indwara; imyenda isanzwe.

Icyitonderwa: Ubushobozi bushoboka nibisabwa byatangijwe muriyi ngingo byose biva mubitabo byasohotse.

Yunnan Hande Biotechnology Co, Ltd yagiye ikora ibijyanye no gukorapaclitaxel APImu myaka irenga 20, kandi ni umwe mu bakora uruganda rwigenga ku isi rwa paclitaxel API, imiti ikomoka ku bimera ikomoka ku kurwanya kanseri, yemejwe na FDA yo muri Amerika, EDQM yo mu Burayi, TGA yo muri Ositaraliya, CFDA y’Ubushinwa, Ubuhinde, Ubuyapani n’izindi nzego zishinzwe kugenzura igihugu. .Hande ntishobora gutanga ubuziranenge gusapaclitaxel ibikoresho fatizo, ariko kandi na serivise yo kuzamura tekinike ijyanye na formulaire ya paclitaxel. Kubindi bisobanuro, nyamuneka twandikire kuri 18187887160.